Experimental gene therapy for blinding eye disease tested, but study stopped early
Disease control
Terminated
This study tested a gene therapy called HORA-PDE6B for people with retinitis pigmentosa caused by a specific genetic defect. The treatment was injected under the retina in one eye to try to improve vision. The study was terminated early, and it is unclear if the therapy was effec…
Phase: PHASE1, PHASE2 • Sponsor: eyeDNA Therapeutics • Aim: Disease control
Last updated May 26, 2026 12:10 UTC